WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), a developer of cell therapy platforms for various diseases and currently valued at $8.34 million, announced today its intent to acquire NexGenAI Affiliates Network, a provider of AI-powered marketing software and robotic process automation (RPA) capabilities. According to InvestingPro data, the company's stock has experienced significant volatility, declining over 74% year-to-date, though analysts maintain a $3.00 price target. This acquisition is aimed at bolstering Coeptis' operational efficiency and expanding its technological offerings.
NexGenAI, a part of NexGenAI Solutions Group, has created a suite of marketing tools that employ artificial intelligence and RPA to improve campaign effectiveness and streamline operations, particularly in the highly regulated biotech and pharmaceutical industries. The integration of these tools is expected to aid companies in conducting more efficient and compliant marketing campaigns.
Dave Mehalick, President and CEO of Coeptis, expressed enthusiasm about incorporating NexGenAI's tools, highlighting the competitive edge and regulatory compliance they can provide in the challenging biotech and pharma sectors. Anshuman Dash, the Lead Advisory behind NexGenAI, also remarked on the transformative potential of this integration with Coeptis' innovative approach.
Coeptis, with a focus on developing cell therapies for cancer, autoimmune, and infectious diseases, is looking to enhance its product offerings through strategic partnerships and acquisitions. The company's portfolio includes licensed assets from Deverra Therapeutics and technologies in development with partners like VyGen-Bio and the Karolinska Institutet.
The acquisition is subject to customary closing conditions and regulatory approvals. Both parties anticipate that the integration of NexGenAI's AI and RPA-driven tools will revolutionize marketing strategies and operational efficiencies, delivering greater value to their partners and the industries they serve. InvestingPro analysis indicates the company currently operates with a moderate level of debt and faces challenges with its current ratio of 0.4, suggesting potential liquidity concerns that this strategic move might help address.
This move is part of Coeptis' broader strategy to leverage innovative technologies to support its biopharmaceutical development efforts. The company has not disclosed the financial terms of the acquisition. With an EBITDA of -$10.26 million in the last twelve months, this strategic pivot could be crucial for the company's future growth. Want deeper insights into Coeptis' financial health and growth potential? InvestingPro subscribers have access to over 30 additional financial metrics and expert analysis tools.
The information in this article is based on a press release statement from Coeptis Therapeutics Holdings, Inc.
In other recent news, Coeptis Therapeutics has expanded its license agreement with Deverra Therapeutics to include the use of unmodified natural killer (NK) cells for pandemic preparedness and emergency use. This development broadens the applicability of NK cells and enhances Coeptis' readiness for future health crises. The company has also completed a Phase 1 clinical trial for COVID-19-related infections and enrolled participants for a separate trial in acute myeloid leukemia and myelodysplastic syndrome.
On the financial front, Coeptis has retracted its financial statements for several periods in 2023 and 2024 due to accounting errors and has appointed Astra Audit & Advisory, LLC as its new independent registered public accounting firm for the fiscal year ending December 31, 2024.
Coeptis is also dealing with regulatory issues, including the risk of delisting from the Nasdaq Capital Market due to failure to meet the Nasdaq's Minimum Bid Price Requirement. However, the company has been granted an extension to remain listed on the Nasdaq until January 15, 2025, provided it demonstrates compliance with the minimum bid price requirement. These are the recent developments at Coeptis Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.